Assessing Potential Drug- Drug Interactions with Integrase Inhibitors in HIV patients.
Not Applicable
- Conditions
- Health Condition 1: B20- Human immunodeficiency virus [HIV]disease
- Registration Number
- CTRI/2022/02/040013
- Lead Sponsor
- Manipal Academy of Higher Education
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
HIV seropositive patients (HIV-SPP) of either sex on INSTI-based and other ART therapies,
from both in-patient and out-patient departments of the study center.
Exclusion Criteria
1. HIV-SPP who refused ART treatment and did not consent to participate in the study.
2. HIV-SPP taking only herbal medicines and medications belonging to Ayurvedic, Homeopathic,
Siddha, and Unani treatments.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The identification, assessment, and documentation of all PDDIs within <br/ ><br>INSTI-based ART therapy and between ART and other therapies in HIV patients. To establish the <br/ ><br>reduced incidence of DDIs in the INSTI-based ART regimens, compared to other ART regimens. <br/ ><br>To report the Incidence and Prevalence rates of the established PDDIs, their mechanism(s), and <br/ ><br>outline the management.Timepoint: Patient files will be screened at the Baseline.
- Secondary Outcome Measures
Name Time Method To report the Incidence and Prevalence rates of the established PDDIs, their mechanism(s), and <br/ ><br>outline the management.Timepoint: Patient files will be screened at the Baseline.